局部晚期头颈癌同步放化疗联合帕博利珠单抗同步与序贯给药的随机II期研究
在局部晚期头颈鳞癌中,同步放化疗联合帕博利珠单抗的最佳时机尚不明确。本II期随机研究将患者1:1分配至同步组(CRT前1周开始帕博利珠单抗200 mg每3周一次×8)或序贯组(CRT后2周开始),两组均满足主要终点,序贯组1年PFS数值更优(84% vs 71%),4年局部区域控制显著更优(96% vs 64%,HR 0.11,P=0.012)。
要点
- 两组均满足三变量主要终点,序贯组1年PFS数值更高(84% vs 71%)。
- 序贯组4年局部区域控制显著优于同步组(96% vs 64%;HR 0.11;P=0.012)。
- 同步组治疗后肿瘤微环境中巨噬细胞、PD-L1+巨噬细胞及PD-L1+肿瘤细胞显著增加,序贯组无此变化。
核心结论
- 同步放化疗联合序贯帕博利珠单抗满足进一步研究的标准。
- 两臂肿瘤微环境中的免疫抑制性改变存在差异,反映同步组中单剂帕博利珠单抗的影响。
研究设计与样本
- II期随机研究,将局部晚期头颈鳞癌患者按1:1随机分配至同步帕博利珠单抗组或序贯帕博利珠单抗组。
- 同步组:帕博利珠单抗200 mg每3周一次×8,于放化疗前1周开始;放化疗为顺铂40 mg/m2每周一次+放疗70 Gy。
- 序贯组:帕博利珠单抗于放化疗后2周开始。
- 纳入HPV阳性(>10包年或T4或N3)及HPV阴性局部晚期头颈鳞癌患者,按HPV状态和N分期分层。
- 采用择优设计:若两臂均满足三变量主要终点(1年局部区域失败<60%、无进展生存≥60%、剂量限制性毒性率≤20%),则选择1年PFS数值更优的臂。
主要发现
- 两臂均满足三变量主要终点,序贯组1年PFS数值更优(84% vs 71%)。
- 4年局部区域控制:序贯组96% vs 同步组64%(HR 0.11,95%CI 0.01至0.89;P=0.012)。
- 4年PFS:序贯组69% vs 同步组49%(HR 0.55,95%CI 0.25至1.22;P=0.132);4年总生存:序贯组83% vs 同步组71%(HR 0.51,95%CI 0.19至1.37;P=0.17)。
- 同步组治疗后巨噬细胞、PD-L1+巨噬细胞及PD-L1+肿瘤细胞显著增加,序贯组无显著变化。
关键数值与推荐
- 三变量主要终点:1年局部区域失败<60%、无进展生存≥60%、剂量限制性毒性率≤20%。
- 择优标准:若两臂均满足主要终点,选择1年PFS数值更优的臂。
临床怎么用
- 原文结论指出同步放化疗联合序贯帕博利珠单抗满足进一步研究的标准。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The optimal timing of pembrolizumab with chemoradiation (CRT) in locally advanced (LA) head and neck squamous cell carcinoma (HNSCC) is unknown. PATIENTS AND METHODS: Our phase II trial randomly assigned patients 1:1 to concurrent pembrolizumab (200 mg once every 3 weeks × 8) starting 1 week before CRT (cisplatin 40 mg/m2 once weekly + radiation 70 Gy) versus sequential pembrolizumab starting 2 weeks after CRT. Human papillomavirus (HPV)+ (>10 pack-years or T4 or N3) and HPV(-) LA HNSCC were included, stratified by HPV and N stage. In our pick-the-winner design, if both arms met the trivariate primary end point (1-year locoregional failure <60%, progression-free survival [PFS] ≥60%, and dose limiting toxicity rate ≤20%), the arm with numerically superior 1-year PFS would be selected. Survival end points were compared by a univariate Cox model. Pretreatment and on-treatment tumor biopsies (week 2 of CRT) were evaluated by multispectral imaging and compared using two-sided paired t-tests. RESULTS: Treated patients (41 concurrent and 39 sequential) were 71% oropharynx (53% HPV+), 92.5% stage IV (46% T4, 76% N2), similar by arm. Both arms met the trivariate primary end point, with superior 1-year PFS in the sequential arm (84% v 71%) and favorable 4-year outcomes: locoregional control (96% v 64%; hazard ratio [HR], 0.11 [95% CI, 0.01 to 0.89]; P = .012), PFS (69% v 49%; HR, 0.55 [95% CI, 0.25 to 1.22]; P = .132), and overall survival (83% v 71%; HR, 0.51 [95% CI, 0.19 to 1.37]; P = .17). There was a significant increase in macrophages, PD-L1+ macrophages, and PD-L1+ tumor cells with treatment in the concurrent but not the sequential arm. CONCLUSION: CRT with sequential pembrolizumab met criteria for further study. Immunosuppressive changes in the TME differed between arms, reflecting the impact of one dose of pembrolizumab in the concurrent arm.
引用
- Zandberg DP, Vujanovic L, Clump DA, et al. Randomized Phase II Study of Concurrent Versus Sequential Pembrolizumab in Combination With Chemoradiation in Locally Advanced Head and Neck Cancer. J Clin Oncol. 2025. PMID: 40424564. doi:10.1200/JCO-24-01580
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。